Hoth Therapeutics, Inc.

HOTH

US44148G2049

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 15:59:53 2024-05-23 EDT			5-day change	1st Jan Change
1.16 ^USD	-3.33%		0.00%	-19.44%

03-28	Hoth Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-19	Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	MT

Hoth Therapeutics Inc. Announces the Addition of Dr. Andrew Herr to its Technology Advisory Board

September 05, 2017 at 08:00 am

Hoth Therapeutics Inc. announced the addition of Dr. Andrew Herr to the company's Technology Advisory Board. The Technology Advisory Board was formed to assist the company in developing the BioLexa Platform. Dr. Andrew Herr, PhD, is an associate professor in the Division of Immunobiology and Center for Systems Immunology, with an affiliate appointment in the Division of Infectious Diseases at Cincinnati Children's Hospital within the UC Department of Pediatrics.

Latest news about Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	03-19	MT
Hoth Therapeutics, Inc. Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ	03-19	CI
HC Wainwright Starts Hoth Therapeutics With Buy Rating, $4 Price Target	02-05	MT
Hoth Therapeutics Shares Rise 14% After FDA Clearance for HT-001 Trial Amendments	01-18	DJ
Hoth Therapeutics Receives FDA Approval to Expand HT-001 Clinical Trial to Treat Severely III Patients	01-18	CI
Hoth Therapeutics Gets University of Miami Approval to Enroll Patients in Skin Toxicities Treatment Trial; Shares Rise	12-27	MT
Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial for Cancer Patients of HT-001 At University of Miami	12-27	CI
Hoth Therapeutics Announces Successfully Completed Manufacturing of its Cancer Fighting HT-KIT for Ind-Enabling Studies	12-05	CI
Hoth Therapeutics to Advance HT-KIT After Positive Feedback From FDA	11-14	MT
Hoth Therapeutics, Inc. Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT	11-14	CI
Hoth Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients	23-10-02	CI
Hoth Therapeutics Completes $2.89 Million Registered Direct Stock Offering	23-09-15	MT
Hoth Therapeutics, Inc. announced that it has received $2.892449 million in funding	23-09-14	CI
EF Hutton Cuts Hoth Therapeutics Price Target to $7.50 From $12, Maintains Buy Rating	23-09-14	MT
Hoth Therapeutics Prices Registered Direct Offering at $2.63 per Share	23-09-13	MT
Hoth Therapeutics, Inc. Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia	23-09-13	CI
Hoth Therapeutics, Inc. announced that it expects to receive $2.892449 million in funding	23-09-12	CI
Hoth Therapeutics Seeks FDA Meeting to Discuss HT-KIT Cancer Drug Program	23-09-11	MT
EF Hutton Assumes Hoth Therapeutics at Buy With $14 Price Target	23-08-23	MT
Hoth Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Hoth Therapeutics, Inc. Doses First Patient in its Phase 2a Clinical Trial of HT-001 for Treatment of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors	23-07-25	CI
Hoth Therapeutics Says FDA Approved Protocol Change in Trial of Treatment for Cancer Therapy-Induced Skin Disorders	23-07-19	MT
Hoth Therapeutics, Inc. Receives Protocol Approval for HT-001 Cancer Therapeutic	23-07-19	CI

Chart Hoth Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimerâs or other neuroinflammatory diseases (HT-ALZ). It also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for acne as well as inflammatory bowel diseases (HT-003). Its development products include HT-001, HT-KIT, HT-ALZ, and HT-TBI. Its BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The Company also has interests in certain other assets being developed by third parties including a treatment for patients with lupus.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.16 USD

Average target price

5.5 USD

Spread / Average Target

+374.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HOTH THERAPEUTICS, INC.	-19.44%	5.87M
ELI LILLY AND COMPANY	+38.69%	723B
NOVO NORDISK A/S	+34.28%	595B
JOHNSON & JOHNSON	-4.49%	369B
MERCK & CO., INC.	+20.24%	332B
ABBVIE INC.	+2.12%	282B
ASTRAZENECA PLC	+17.02%	244B
NOVARTIS AG	+9.31%	208B
ROCHE HOLDING AG	-5.07%	205B
PFIZER, INC.	-0.35%	168B

Other Pharmaceuticals